Complex karyotypes and their prognostic value in CLL
Bone marrow transplant consent: insight into patient motivations
Can chemoimmunotherapy in CLL treatment be replaced with novel agents?
ASCO 2016 highlights for CLL
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL